| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Crohn Disease | 208 | 2023 | 730 | 27.030 |
Why?
|
| Colitis, Ulcerative | 169 | 2024 | 711 | 20.660 |
Why?
|
| Inflammatory Bowel Diseases | 82 | 2023 | 549 | 16.730 |
Why?
|
| Gastrointestinal Agents | 52 | 2021 | 161 | 9.910 |
Why?
|
| Anti-Inflammatory Agents, Non-Steroidal | 48 | 2021 | 243 | 7.230 |
Why?
|
| Anti-Inflammatory Agents | 50 | 2020 | 339 | 7.000 |
Why?
|
| Immunosuppressive Agents | 65 | 2021 | 977 | 6.900 |
Why?
|
| Mesalamine | 45 | 2020 | 88 | 6.830 |
Why?
|
| Antibodies, Monoclonal | 70 | 2023 | 1376 | 6.770 |
Why?
|
| Gastroenterology | 14 | 2020 | 140 | 4.740 |
Why?
|
| Tumor Necrosis Factor-alpha | 43 | 2023 | 683 | 3.940 |
Why?
|
| Biological Therapy | 16 | 2020 | 45 | 3.780 |
Why?
|
| Humans | 477 | 2024 | 86678 | 3.760 |
Why?
|
| Colitis | 13 | 2024 | 239 | 3.660 |
Why?
|
| Biological Products | 13 | 2023 | 143 | 3.610 |
Why?
|
| Azathioprine | 22 | 2021 | 125 | 3.330 |
Why?
|
| Remission Induction | 74 | 2023 | 722 | 3.120 |
Why?
|
| Infliximab | 52 | 2022 | 151 | 3.110 |
Why?
|
| Immunologic Factors | 14 | 2021 | 170 | 3.020 |
Why?
|
| Aminosalicylic Acids | 29 | 2016 | 42 | 2.860 |
Why?
|
| Treatment Outcome | 122 | 2023 | 7998 | 2.740 |
Why?
|
| Adalimumab | 21 | 2023 | 80 | 2.700 |
Why?
|
| Stress Disorders, Post-Traumatic | 5 | 2023 | 96 | 2.590 |
Why?
|
| Severity of Illness Index | 60 | 2021 | 1802 | 2.520 |
Why?
|
| Double-Blind Method | 82 | 2023 | 1824 | 2.430 |
Why?
|
| Mercaptopurine | 13 | 2018 | 53 | 2.380 |
Why?
|
| Adrenal Cortex Hormones | 25 | 2022 | 263 | 2.370 |
Why?
|
| Adult | 192 | 2023 | 25659 | 2.130 |
Why?
|
| Antibodies, Monoclonal, Humanized | 37 | 2021 | 930 | 2.000 |
Why?
|
| Biosimilar Pharmaceuticals | 3 | 2023 | 20 | 1.950 |
Why?
|
| Female | 210 | 2023 | 44550 | 1.900 |
Why?
|
| Sulfasalazine | 18 | 2016 | 34 | 1.880 |
Why?
|
| Ustekinumab | 9 | 2023 | 47 | 1.850 |
Why?
|
| Male | 199 | 2022 | 40988 | 1.840 |
Why?
|
| Colonoscopy | 24 | 2021 | 267 | 1.840 |
Why?
|
| Arthritis, Rheumatoid | 5 | 2023 | 166 | 1.830 |
Why?
|
| Clinical Trials as Topic | 23 | 2017 | 1169 | 1.810 |
Why?
|
| Methotrexate | 12 | 2022 | 249 | 1.800 |
Why?
|
| Intestinal Mucosa | 25 | 2020 | 797 | 1.790 |
Why?
|
| Colorectal Neoplasms | 15 | 2024 | 938 | 1.780 |
Why?
|
| Glucocorticoids | 19 | 2014 | 352 | 1.780 |
Why?
|
| Pharmaceutical Preparations | 3 | 2021 | 92 | 1.680 |
Why?
|
| Middle Aged | 144 | 2023 | 25040 | 1.620 |
Why?
|
| Induction Chemotherapy | 12 | 2023 | 147 | 1.620 |
Why?
|
| Cyclosporine | 13 | 2018 | 234 | 1.600 |
Why?
|
| Smoking | 15 | 2020 | 609 | 1.570 |
Why?
|
| Colectomy | 22 | 2018 | 167 | 1.570 |
Why?
|
| Digestive System Diseases | 6 | 2010 | 18 | 1.520 |
Why?
|
| Drug Therapy, Combination | 26 | 2018 | 895 | 1.480 |
Why?
|
| Biomedical Research | 7 | 2010 | 376 | 1.420 |
Why?
|
| Drug Monitoring | 8 | 2020 | 118 | 1.410 |
Why?
|
| Diarrhea | 9 | 2021 | 182 | 1.410 |
Why?
|
| Fellowships and Scholarships | 2 | 2020 | 110 | 1.380 |
Why?
|
| Drug Industry | 4 | 2009 | 54 | 1.260 |
Why?
|
| Pyrimidines | 2 | 2021 | 370 | 1.200 |
Why?
|
| Randomized Controlled Trials as Topic | 22 | 2022 | 865 | 1.200 |
Why?
|
| Colon | 25 | 2020 | 496 | 1.180 |
Why?
|
| Nicotine | 8 | 2012 | 194 | 1.180 |
Why?
|
| Secondary Prevention | 9 | 2020 | 162 | 1.180 |
Why?
|
| Education, Medical, Graduate | 2 | 2020 | 373 | 1.130 |
Why?
|
| United States | 36 | 2023 | 6681 | 1.110 |
Why?
|
| Budesonide | 10 | 2016 | 45 | 1.080 |
Why?
|
| Immunoglobulin Fab Fragments | 10 | 2014 | 81 | 1.070 |
Why?
|
| Serum | 2 | 2015 | 25 | 1.040 |
Why?
|
| Anti-Infective Agents | 8 | 2013 | 90 | 1.030 |
Why?
|
| Vitamin D | 4 | 2016 | 261 | 1.020 |
Why?
|
| Evidence-Based Medicine | 8 | 2011 | 429 | 1.010 |
Why?
|
| Anti-Bacterial Agents | 15 | 2011 | 747 | 1.010 |
Why?
|
| Dose-Response Relationship, Drug | 38 | 2022 | 1961 | 1.010 |
Why?
|
| Certolizumab Pegol | 11 | 2016 | 19 | 1.000 |
Why?
|
| Safety | 9 | 2021 | 152 | 1.000 |
Why?
|
| Loperamide | 4 | 2008 | 7 | 1.000 |
Why?
|
| Antidiarrheals | 4 | 2008 | 14 | 0.980 |
Why?
|
| Drug Administration Schedule | 23 | 2020 | 916 | 0.980 |
Why?
|
| Quality of Life | 25 | 2023 | 1585 | 0.970 |
Why?
|
| Biomarkers | 13 | 2022 | 1718 | 0.950 |
Why?
|
| Polyethylene Glycols | 10 | 2014 | 364 | 0.950 |
Why?
|
| Health Care Reform | 3 | 2010 | 90 | 0.940 |
Why?
|
| Semen | 2 | 2022 | 13 | 0.920 |
Why?
|
| Travel | 3 | 2010 | 68 | 0.920 |
Why?
|
| Allopurinol | 5 | 2018 | 80 | 0.920 |
Why?
|
| Maintenance Chemotherapy | 13 | 2021 | 76 | 0.920 |
Why?
|
| Irritable Bowel Syndrome | 3 | 2008 | 45 | 0.900 |
Why?
|
| Janus Kinase Inhibitors | 1 | 2023 | 19 | 0.900 |
Why?
|
| Drug Resistance | 13 | 2014 | 256 | 0.890 |
Why?
|
| Nicotinic Agonists | 3 | 2012 | 72 | 0.880 |
Why?
|
| Risk Assessment | 13 | 2019 | 2264 | 0.870 |
Why?
|
| Semen Analysis | 1 | 2022 | 2 | 0.870 |
Why?
|
| Practice Guidelines as Topic | 11 | 2016 | 1037 | 0.860 |
Why?
|
| Aged | 70 | 2021 | 18423 | 0.850 |
Why?
|
| Placebos | 12 | 2018 | 218 | 0.840 |
Why?
|
| Piperidines | 3 | 2021 | 181 | 0.840 |
Why?
|
| Atrioventricular Block | 1 | 2022 | 23 | 0.840 |
Why?
|
| Europe | 9 | 2023 | 309 | 0.810 |
Why?
|
| Diet, Mediterranean | 1 | 2021 | 6 | 0.810 |
Why?
|
| Prodrugs | 4 | 2013 | 46 | 0.800 |
Why?
|
| Pyrroles | 2 | 2021 | 184 | 0.790 |
Why?
|
| Adolescent | 55 | 2021 | 8984 | 0.780 |
Why?
|
| Colonic Neoplasms | 11 | 2018 | 558 | 0.780 |
Why?
|
| Recurrence | 22 | 2020 | 1139 | 0.770 |
Why?
|
| Steroids | 12 | 2011 | 177 | 0.750 |
Why?
|
| Indans | 4 | 2022 | 31 | 0.750 |
Why?
|
| Patient Selection | 8 | 2011 | 686 | 0.750 |
Why?
|
| Competency-Based Education | 1 | 2020 | 35 | 0.750 |
Why?
|
| Diagnostic Imaging | 4 | 2014 | 469 | 0.750 |
Why?
|
| C-Reactive Protein | 14 | 2022 | 190 | 0.740 |
Why?
|
| Global Health | 5 | 2011 | 193 | 0.740 |
Why?
|
| Oxadiazoles | 4 | 2022 | 46 | 0.740 |
Why?
|
| Precancerous Conditions | 4 | 2016 | 196 | 0.730 |
Why?
|
| Psychopathology | 1 | 2019 | 29 | 0.710 |
Why?
|
| Time-to-Treatment | 1 | 2020 | 98 | 0.700 |
Why?
|
| alpha-Fetoproteins | 1 | 2019 | 45 | 0.690 |
Why?
|
| Diet | 4 | 2021 | 443 | 0.690 |
Why?
|
| Antibodies | 10 | 2016 | 350 | 0.680 |
Why?
|
| Administration, Oral | 18 | 2016 | 684 | 0.680 |
Why?
|
| Young Adult | 35 | 2021 | 5980 | 0.670 |
Why?
|
| Gastrointestinal Tract | 2 | 2014 | 191 | 0.660 |
Why?
|
| Conflict of Interest | 3 | 2009 | 67 | 0.650 |
Why?
|
| Purines | 1 | 2018 | 91 | 0.640 |
Why?
|
| Time Factors | 33 | 2020 | 5214 | 0.630 |
Why?
|
| Follow-Up Studies | 22 | 2019 | 3642 | 0.630 |
Why?
|
| Chronic Disease | 10 | 2022 | 973 | 0.630 |
Why?
|
| Health Care Costs | 3 | 2009 | 239 | 0.620 |
Why?
|
| Antineoplastic Agents, Immunological | 1 | 2020 | 185 | 0.610 |
Why?
|
| Primary Prevention | 2 | 2008 | 85 | 0.610 |
Why?
|
| Ulcer | 3 | 2006 | 36 | 0.580 |
Why?
|
| Vitamin D Deficiency | 3 | 2016 | 103 | 0.580 |
Why?
|
| Interleukin-23 | 1 | 2017 | 54 | 0.580 |
Why?
|
| Prognosis | 20 | 2020 | 3680 | 0.580 |
Why?
|
| Drug Approval | 2 | 2007 | 62 | 0.580 |
Why?
|
| Anti-Ulcer Agents | 4 | 2005 | 22 | 0.580 |
Why?
|
| Gastrointestinal Diseases | 3 | 2008 | 146 | 0.570 |
Why?
|
| Risk Factors | 22 | 2021 | 5420 | 0.570 |
Why?
|
| Food | 3 | 2021 | 86 | 0.570 |
Why?
|
| Sigmoidoscopy | 11 | 2015 | 36 | 0.560 |
Why?
|
| Cholangitis, Sclerosing | 5 | 2020 | 52 | 0.560 |
Why?
|
| Gastrointestinal Hemorrhage | 4 | 2020 | 230 | 0.560 |
Why?
|
| Enema | 7 | 2008 | 37 | 0.560 |
Why?
|
| Proctocolectomy, Restorative | 2 | 2012 | 87 | 0.550 |
Why?
|
| Trichuris | 2 | 2013 | 2 | 0.550 |
Why?
|
| Injections, Subcutaneous | 8 | 2021 | 117 | 0.530 |
Why?
|
| Enterocolitis | 2 | 2022 | 12 | 0.530 |
Why?
|
| Wound Healing | 8 | 2020 | 344 | 0.520 |
Why?
|
| Granulocytes | 2 | 2012 | 37 | 0.520 |
Why?
|
| Blood Component Removal | 2 | 2012 | 24 | 0.510 |
Why?
|
| Infusions, Intravenous | 15 | 2016 | 430 | 0.500 |
Why?
|
| Academic Medical Centers | 2 | 2009 | 380 | 0.500 |
Why?
|
| Delayed-Action Preparations | 9 | 2016 | 116 | 0.490 |
Why?
|
| History, 20th Century | 5 | 2012 | 312 | 0.490 |
Why?
|
| Clinical Competence | 3 | 2020 | 756 | 0.490 |
Why?
|
| Pneumonia | 2 | 2015 | 179 | 0.490 |
Why?
|
| Patient Satisfaction | 5 | 2011 | 455 | 0.490 |
Why?
|
| Metabolic Syndrome | 2 | 2006 | 142 | 0.480 |
Why?
|
| Monocytes | 4 | 2012 | 216 | 0.480 |
Why?
|
| Societies, Medical | 2 | 2015 | 573 | 0.480 |
Why?
|
| Delivery of Health Care | 2 | 2009 | 426 | 0.480 |
Why?
|
| Diverticulitis | 1 | 2013 | 9 | 0.480 |
Why?
|
| Intestinal Polyps | 2 | 2008 | 26 | 0.470 |
Why?
|
| Therapy with Helminths | 1 | 2013 | 1 | 0.470 |
Why?
|
| Antigens, Helminth | 1 | 2013 | 22 | 0.460 |
Why?
|
| Tacrolimus | 3 | 2011 | 373 | 0.450 |
Why?
|
| Diverticulum | 1 | 2013 | 44 | 0.450 |
Why?
|
| Ovum | 1 | 2013 | 58 | 0.450 |
Why?
|
| Ileostomy | 3 | 2012 | 30 | 0.450 |
Why?
|
| Life Style | 3 | 2008 | 189 | 0.450 |
Why?
|
| Antimetabolites | 4 | 2011 | 24 | 0.450 |
Why?
|
| Thioguanine | 5 | 2018 | 17 | 0.440 |
Why?
|
| Treatment Refusal | 3 | 2011 | 60 | 0.440 |
Why?
|
| Radiation Injuries | 2 | 2014 | 156 | 0.440 |
Why?
|
| Obesity | 4 | 2008 | 964 | 0.440 |
Why?
|
| Postoperative Complications | 8 | 2018 | 2207 | 0.430 |
Why?
|
| Biomarkers, Tumor | 3 | 2019 | 1464 | 0.420 |
Why?
|
| Carnitine | 1 | 2012 | 14 | 0.420 |
Why?
|
| Surgical Stomas | 1 | 2012 | 22 | 0.420 |
Why?
|
| Allergens | 1 | 2013 | 179 | 0.420 |
Why?
|
| Population Surveillance | 5 | 2016 | 219 | 0.420 |
Why?
|
| Colonic Polyps | 2 | 2018 | 127 | 0.420 |
Why?
|
| Intestinal Fistula | 5 | 2016 | 30 | 0.410 |
Why?
|
| History, 21st Century | 4 | 2012 | 175 | 0.410 |
Why?
|
| Colonic Diseases, Functional | 3 | 2003 | 3 | 0.410 |
Why?
|
| Biological Factors | 3 | 2019 | 18 | 0.400 |
Why?
|
| Pregnancy | 12 | 2019 | 2894 | 0.400 |
Why?
|
| Health Promotion | 3 | 2008 | 160 | 0.400 |
Why?
|
| Vitamins | 2 | 2016 | 81 | 0.390 |
Why?
|
| Endoscopy, Gastrointestinal | 7 | 2013 | 153 | 0.390 |
Why?
|
| Disease Outbreaks | 2 | 2009 | 154 | 0.390 |
Why?
|
| Biopsy | 11 | 2020 | 1163 | 0.380 |
Why?
|
| Inflammation | 7 | 2023 | 923 | 0.380 |
Why?
|
| Case-Control Studies | 16 | 2023 | 1807 | 0.380 |
Why?
|
| Neutrophils | 3 | 2024 | 307 | 0.380 |
Why?
|
| Hypertension, Portal | 1 | 2010 | 47 | 0.380 |
Why?
|
| Physicians | 2 | 2009 | 674 | 0.380 |
Why?
|
| Leukapheresis | 3 | 2008 | 19 | 0.380 |
Why?
|
| Otitis Media | 1 | 2010 | 18 | 0.370 |
Why?
|
| Cephalosporins | 1 | 2010 | 24 | 0.370 |
Why?
|
| Health Behavior | 2 | 2009 | 183 | 0.370 |
Why?
|
| Prednisolone | 3 | 2018 | 41 | 0.360 |
Why?
|
| Education, Medical, Continuing | 2 | 2011 | 107 | 0.360 |
Why?
|
| Peptic Ulcer | 1 | 2009 | 19 | 0.350 |
Why?
|
| Self Disclosure | 1 | 2009 | 31 | 0.350 |
Why?
|
| Proctitis | 2 | 2000 | 12 | 0.350 |
Why?
|
| Esophagitis | 1 | 2009 | 43 | 0.350 |
Why?
|
| Specialization | 1 | 2010 | 65 | 0.350 |
Why?
|
| Safety Management | 1 | 2009 | 56 | 0.350 |
Why?
|
| Outsourced Services | 1 | 2009 | 1 | 0.350 |
Why?
|
| Consumer Product Safety | 1 | 2009 | 11 | 0.350 |
Why?
|
| Commerce | 1 | 2009 | 29 | 0.350 |
Why?
|
| Proton Pump Inhibitors | 1 | 2009 | 32 | 0.350 |
Why?
|
| Body Temperature Regulation | 1 | 2009 | 56 | 0.350 |
Why?
|
| Financial Support | 1 | 2009 | 7 | 0.350 |
Why?
|
| Food Contamination | 1 | 2009 | 31 | 0.340 |
Why?
|
| Food Supply | 1 | 2009 | 28 | 0.340 |
Why?
|
| Uncertainty | 2 | 2021 | 71 | 0.340 |
Why?
|
| Adipose Tissue, Brown | 1 | 2009 | 80 | 0.340 |
Why?
|
| Sulfapyridine | 1 | 2008 | 2 | 0.330 |
Why?
|
| Abdominal Pain | 2 | 2007 | 137 | 0.330 |
Why?
|
| Muscle Hypotonia | 1 | 2009 | 45 | 0.330 |
Why?
|
| Jet Lag Syndrome | 1 | 2008 | 13 | 0.330 |
Why?
|
| Drug-Related Side Effects and Adverse Reactions | 4 | 2017 | 199 | 0.330 |
Why?
|
| Drug Delivery Systems | 2 | 2007 | 178 | 0.320 |
Why?
|
| Surveys and Questionnaires | 11 | 2019 | 2504 | 0.320 |
Why?
|
| Happiness | 1 | 2008 | 12 | 0.320 |
Why?
|
| Retrospective Studies | 24 | 2020 | 8496 | 0.320 |
Why?
|
| Histamine Antagonists | 1 | 2008 | 12 | 0.320 |
Why?
|
| Self Efficacy | 1 | 2008 | 53 | 0.320 |
Why?
|
| Task Performance and Analysis | 1 | 2008 | 86 | 0.320 |
Why?
|
| Cost-Benefit Analysis | 4 | 2021 | 455 | 0.320 |
Why?
|
| Immunity, Innate | 2 | 2014 | 409 | 0.310 |
Why?
|
| Marketing | 1 | 2008 | 23 | 0.310 |
Why?
|
| Periodicals as Topic | 1 | 2010 | 168 | 0.310 |
Why?
|
| Prednisone | 8 | 2007 | 258 | 0.310 |
Why?
|
| Risk Reduction Behavior | 1 | 2008 | 98 | 0.310 |
Why?
|
| Legislation as Topic | 1 | 2007 | 3 | 0.310 |
Why?
|
| Ileal Diseases | 2 | 2004 | 25 | 0.310 |
Why?
|
| Prevalence | 6 | 2022 | 1239 | 0.310 |
Why?
|
| Fasting | 1 | 2008 | 161 | 0.310 |
Why?
|
| Behavior | 1 | 2008 | 85 | 0.310 |
Why?
|
| Measles-Mumps-Rubella Vaccine | 1 | 2007 | 7 | 0.310 |
Why?
|
| Feces | 4 | 2021 | 319 | 0.310 |
Why?
|
| Gastroesophageal Reflux | 1 | 2009 | 117 | 0.310 |
Why?
|
| Clinical Trials, Phase I as Topic | 1 | 2008 | 155 | 0.310 |
Why?
|
| Antirheumatic Agents | 4 | 2011 | 54 | 0.310 |
Why?
|
| Simethicone | 1 | 2007 | 1 | 0.310 |
Why?
|
| Flatulence | 1 | 2007 | 2 | 0.310 |
Why?
|
| Health Priorities | 1 | 2007 | 23 | 0.300 |
Why?
|
| Retreatment | 5 | 2016 | 107 | 0.300 |
Why?
|
| Terminology as Topic | 2 | 2011 | 217 | 0.300 |
Why?
|
| Gastrointestinal Motility | 1 | 2007 | 25 | 0.300 |
Why?
|
| Liver Diseases | 2 | 2008 | 241 | 0.300 |
Why?
|
| Nutritional Physiological Phenomena | 1 | 2007 | 27 | 0.300 |
Why?
|
| Diagnosis, Differential | 8 | 2010 | 1566 | 0.300 |
Why?
|
| Energy Metabolism | 1 | 2009 | 271 | 0.300 |
Why?
|
| Quality of Health Care | 2 | 2012 | 381 | 0.300 |
Why?
|
| Nutrition Assessment | 1 | 2007 | 21 | 0.300 |
Why?
|
| Economic Competition | 1 | 2006 | 12 | 0.300 |
Why?
|
| Patents as Topic | 1 | 2006 | 12 | 0.290 |
Why?
|
| Insemination, Artificial, Homologous | 1 | 2006 | 4 | 0.290 |
Why?
|
| Immunity | 1 | 2008 | 136 | 0.290 |
Why?
|
| Biodiversity | 1 | 2009 | 197 | 0.290 |
Why?
|
| Abdominal Abscess | 2 | 2016 | 22 | 0.290 |
Why?
|
| Phosphodiesterase Inhibitors | 1 | 2006 | 30 | 0.290 |
Why?
|
| Neoplasms | 4 | 2021 | 2898 | 0.290 |
Why?
|
| Occupational Health | 1 | 2007 | 32 | 0.290 |
Why?
|
| United States Food and Drug Administration | 1 | 2007 | 127 | 0.290 |
Why?
|
| Ethics, Medical | 1 | 2009 | 306 | 0.290 |
Why?
|
| Ovulation Induction | 1 | 2006 | 33 | 0.290 |
Why?
|
| Drugs, Generic | 1 | 2006 | 21 | 0.290 |
Why?
|
| Health Expenditures | 1 | 2007 | 86 | 0.290 |
Why?
|
| Observation | 1 | 2006 | 37 | 0.290 |
Why?
|
| Nobel Prize | 1 | 2006 | 10 | 0.290 |
Why?
|
| Autistic Disorder | 1 | 2007 | 147 | 0.280 |
Why?
|
| Contraceptives, Oral | 3 | 1991 | 46 | 0.280 |
Why?
|
| Prospective Studies | 19 | 2023 | 4214 | 0.280 |
Why?
|
| Infertility | 1 | 2006 | 37 | 0.280 |
Why?
|
| Integrins | 3 | 2021 | 76 | 0.280 |
Why?
|
| Self Concept | 1 | 2007 | 133 | 0.280 |
Why?
|
| Ileum | 7 | 2016 | 159 | 0.280 |
Why?
|
| Pandemics | 2 | 2022 | 740 | 0.280 |
Why?
|
| Vibrio Infections | 1 | 2005 | 2 | 0.280 |
Why?
|
| Disease Management | 4 | 2018 | 327 | 0.280 |
Why?
|
| Research Design | 6 | 2020 | 594 | 0.280 |
Why?
|
| Thiazoles | 1 | 2006 | 131 | 0.280 |
Why?
|
| Genetics | 1 | 2006 | 24 | 0.270 |
Why?
|
| Hospitalization | 5 | 2023 | 851 | 0.270 |
Why?
|
| Natalizumab | 7 | 2013 | 21 | 0.270 |
Why?
|
| Gastroenteritis | 1 | 2005 | 27 | 0.270 |
Why?
|
| Cell Transformation, Neoplastic | 2 | 2010 | 427 | 0.270 |
Why?
|
| Climate | 1 | 2005 | 50 | 0.270 |
Why?
|
| Private Practice | 1 | 2005 | 11 | 0.270 |
Why?
|
| Circadian Rhythm | 1 | 2008 | 303 | 0.270 |
Why?
|
| Aged, 80 and over | 12 | 2019 | 6513 | 0.270 |
Why?
|
| Spermatozoa | 2 | 2022 | 62 | 0.270 |
Why?
|
| Symptom Assessment | 3 | 2020 | 65 | 0.270 |
Why?
|
| Unemployment | 1 | 2005 | 8 | 0.270 |
Why?
|
| Ethics Committees, Research | 1 | 2005 | 33 | 0.260 |
Why?
|
| Foodborne Diseases | 1 | 2005 | 8 | 0.260 |
Why?
|
| Human Experimentation | 1 | 2005 | 39 | 0.260 |
Why?
|
| Researcher-Subject Relations | 1 | 2005 | 4 | 0.260 |
Why?
|
| Intestine, Small | 6 | 2021 | 303 | 0.260 |
Why?
|
| Journalism, Medical | 1 | 2004 | 6 | 0.260 |
Why?
|
| Stress, Psychological | 1 | 2008 | 313 | 0.260 |
Why?
|
| Pregnancy Complications | 3 | 2004 | 336 | 0.250 |
Why?
|
| Peer Review | 1 | 2004 | 24 | 0.250 |
Why?
|
| Ultrasonography | 2 | 2018 | 695 | 0.250 |
Why?
|
| Stem Cell Transplantation | 1 | 2006 | 183 | 0.250 |
Why?
|
| Rectal Fistula | 3 | 2014 | 18 | 0.250 |
Why?
|
| Dietary Supplements | 1 | 2005 | 128 | 0.250 |
Why?
|
| HLA-DR Antigens | 1 | 2004 | 61 | 0.250 |
Why?
|
| Ileitis | 3 | 2011 | 7 | 0.250 |
Why?
|
| Disability Evaluation | 1 | 2005 | 136 | 0.250 |
Why?
|
| Stents | 1 | 2007 | 377 | 0.250 |
Why?
|
| HLA-DQ Antigens | 1 | 2004 | 52 | 0.250 |
Why?
|
| Pain | 2 | 2023 | 391 | 0.240 |
Why?
|
| Acute Disease | 9 | 2011 | 826 | 0.240 |
Why?
|
| Cell- and Tissue-Based Therapy | 2 | 2015 | 49 | 0.240 |
Why?
|
| Animals | 15 | 2024 | 26590 | 0.240 |
Why?
|
| Serum Albumin | 2 | 2019 | 130 | 0.240 |
Why?
|
| MicroRNAs | 4 | 2021 | 534 | 0.240 |
Why?
|
| Feeding Behavior | 1 | 2007 | 324 | 0.240 |
Why?
|
| Disease Progression | 6 | 2016 | 1532 | 0.240 |
Why?
|
| Intestines | 3 | 2020 | 411 | 0.240 |
Why?
|
| Cecal Diseases | 1 | 2003 | 5 | 0.240 |
Why?
|
| Aging | 1 | 2009 | 691 | 0.240 |
Why?
|
| Career Choice | 1 | 2005 | 142 | 0.240 |
Why?
|
| Vagus Nerve Stimulation | 1 | 2023 | 9 | 0.240 |
Why?
|
| Enterocolitis, Pseudomembranous | 3 | 2011 | 52 | 0.240 |
Why?
|
| Osteoporosis | 1 | 2005 | 121 | 0.240 |
Why?
|
| Employment | 1 | 2004 | 52 | 0.240 |
Why?
|
| Organ Transplantation | 1 | 2007 | 265 | 0.230 |
Why?
|
| Congresses as Topic | 3 | 2010 | 116 | 0.230 |
Why?
|
| Lactoferrin | 1 | 2003 | 11 | 0.230 |
Why?
|
| DNA Breaks, Double-Stranded | 2 | 2021 | 64 | 0.230 |
Why?
|
| Lupus Vulgaris | 1 | 2003 | 4 | 0.230 |
Why?
|
| Adenocarcinoma | 3 | 2018 | 1169 | 0.230 |
Why?
|
| Intracellular Signaling Peptides and Proteins | 4 | 2010 | 379 | 0.230 |
Why?
|
| Fetus | 1 | 2004 | 226 | 0.230 |
Why?
|
| Lung Diseases | 1 | 2005 | 263 | 0.230 |
Why?
|
| Adipose Tissue | 1 | 2005 | 241 | 0.220 |
Why?
|
| Fibroblast Growth Factors | 1 | 2003 | 80 | 0.220 |
Why?
|
| Adjuvants, Immunologic | 4 | 2009 | 167 | 0.220 |
Why?
|
| Placenta | 2 | 2015 | 175 | 0.220 |
Why?
|
| Clinical Trials, Phase III as Topic | 2 | 2018 | 172 | 0.220 |
Why?
|
| Anus Diseases | 2 | 2003 | 14 | 0.220 |
Why?
|
| Incidence | 8 | 2020 | 1578 | 0.210 |
Why?
|
| Education, Medical | 1 | 2005 | 234 | 0.210 |
Why?
|
| Calcineurin Inhibitors | 2 | 2013 | 54 | 0.210 |
Why?
|
| Pentanoic Acids | 1 | 2002 | 6 | 0.210 |
Why?
|
| Cycloserine | 1 | 2001 | 5 | 0.210 |
Why?
|
| Genetic Predisposition to Disease | 9 | 2010 | 2271 | 0.200 |
Why?
|
| Chicago | 4 | 2018 | 1380 | 0.200 |
Why?
|
| DNA End-Joining Repair | 1 | 2021 | 3 | 0.200 |
Why?
|
| Carbohydrates | 1 | 2021 | 47 | 0.200 |
Why?
|
| Graft Rejection | 1 | 2007 | 1065 | 0.200 |
Why?
|
| Administration, Topical | 4 | 2016 | 95 | 0.200 |
Why?
|
| Interleukin-12 | 1 | 2021 | 108 | 0.200 |
Why?
|
| Symptom Flare Up | 2 | 2021 | 11 | 0.200 |
Why?
|
| CD3 Complex | 3 | 2014 | 135 | 0.200 |
Why?
|
| Patient Reported Outcome Measures | 1 | 2022 | 166 | 0.190 |
Why?
|
| Phenylhydrazines | 5 | 2005 | 10 | 0.190 |
Why?
|
| Leukocyte L1 Antigen Complex | 4 | 2023 | 39 | 0.190 |
Why?
|
| Mycophenolic Acid | 1 | 2001 | 87 | 0.190 |
Why?
|
| Chemoprevention | 3 | 2006 | 91 | 0.190 |
Why?
|
| DNA | 3 | 2022 | 1294 | 0.190 |
Why?
|
| Graft vs Host Disease | 1 | 2022 | 365 | 0.180 |
Why?
|
| Erythrocyte Count | 1 | 2019 | 23 | 0.180 |
Why?
|
| Ipilimumab | 1 | 2020 | 58 | 0.180 |
Why?
|
| Hematocrit | 1 | 2019 | 68 | 0.180 |
Why?
|
| Erythema Nodosum | 2 | 2006 | 4 | 0.180 |
Why?
|
| Pyridines | 1 | 2002 | 310 | 0.180 |
Why?
|
| Pouchitis | 2 | 2012 | 44 | 0.180 |
Why?
|
| Logistic Models | 5 | 2006 | 1188 | 0.180 |
Why?
|
| Thalidomide | 1 | 1999 | 54 | 0.180 |
Why?
|
| Genetic Linkage | 5 | 2002 | 623 | 0.180 |
Why?
|
| CTLA-4 Antigen | 1 | 2020 | 135 | 0.180 |
Why?
|
| Platelet Count | 1 | 2019 | 92 | 0.180 |
Why?
|
| Forecasting | 3 | 2008 | 305 | 0.170 |
Why?
|
| Psoriasis | 1 | 2022 | 240 | 0.170 |
Why?
|
| Neurons | 1 | 2008 | 1547 | 0.170 |
Why?
|
| Indoles | 3 | 2009 | 318 | 0.170 |
Why?
|
| Blood Proteins | 1 | 2019 | 144 | 0.170 |
Why?
|
| Lymphoproliferative Disorders | 1 | 1999 | 107 | 0.170 |
Why?
|
| Hemoglobins | 1 | 2019 | 179 | 0.170 |
Why?
|
| Long-Term Care | 4 | 2017 | 61 | 0.170 |
Why?
|
| Programmed Cell Death 1 Receptor | 1 | 2020 | 159 | 0.160 |
Why?
|
| Rectum | 6 | 2011 | 146 | 0.160 |
Why?
|
| Genomic Instability | 1 | 2019 | 79 | 0.160 |
Why?
|
| Treatment Failure | 4 | 2014 | 286 | 0.160 |
Why?
|
| Interleukin-6 | 2 | 2017 | 256 | 0.160 |
Why?
|
| Menstrual Cycle | 1 | 1998 | 55 | 0.160 |
Why?
|
| Retroperitoneal Neoplasms | 1 | 1998 | 43 | 0.160 |
Why?
|
| Stomatitis, Aphthous | 1 | 1998 | 4 | 0.160 |
Why?
|
| Autoimmune Diseases | 2 | 2002 | 241 | 0.160 |
Why?
|
| Sensitivity and Specificity | 3 | 2010 | 1992 | 0.160 |
Why?
|
| Cardiovascular Diseases | 1 | 2005 | 827 | 0.160 |
Why?
|
| Prostatic Neoplasms | 2 | 2020 | 1721 | 0.160 |
Why?
|
| Pyoderma Gangrenosum | 1 | 1998 | 19 | 0.160 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 5 | 2021 | 2438 | 0.160 |
Why?
|
| B7-H1 Antigen | 1 | 2020 | 250 | 0.160 |
Why?
|
| Child | 11 | 2013 | 6928 | 0.160 |
Why?
|
| Aspirin | 1 | 2019 | 156 | 0.160 |
Why?
|
| Fecal Incontinence | 2 | 2008 | 57 | 0.160 |
Why?
|
| Thrombospondins | 1 | 2017 | 14 | 0.150 |
Why?
|
| Caveolin 1 | 1 | 2017 | 20 | 0.150 |
Why?
|
| Parenteral Nutrition, Total | 4 | 2005 | 41 | 0.150 |
Why?
|
| Lymphoma, B-Cell | 1 | 1998 | 103 | 0.150 |
Why?
|
| Tumor Microenvironment | 1 | 2021 | 418 | 0.150 |
Why?
|
| Pilot Projects | 7 | 2013 | 840 | 0.150 |
Why?
|
| Antibody Formation | 2 | 2011 | 171 | 0.150 |
Why?
|
| Cohort Studies | 4 | 2019 | 2768 | 0.150 |
Why?
|
| Paternal Exposure | 1 | 2017 | 3 | 0.150 |
Why?
|
| Colonic Diseases | 3 | 2006 | 65 | 0.150 |
Why?
|
| Meta-Analysis as Topic | 2 | 2009 | 87 | 0.150 |
Why?
|
| Standard of Care | 1 | 2018 | 79 | 0.150 |
Why?
|
| Collagen Type I | 1 | 2017 | 62 | 0.150 |
Why?
|
| Legislation, Drug | 2 | 2007 | 7 | 0.150 |
Why?
|
| Gastrointestinal Microbiome | 2 | 2020 | 456 | 0.150 |
Why?
|
| Protein-Losing Enteropathies | 1 | 1996 | 6 | 0.150 |
Why?
|
| Practice Patterns, Physicians' | 2 | 2016 | 584 | 0.150 |
Why?
|
| Lymphoma, Large B-Cell, Diffuse | 1 | 1998 | 151 | 0.150 |
Why?
|
| Injections, Intravenous | 4 | 2018 | 244 | 0.150 |
Why?
|
| Focal Adhesions | 1 | 2017 | 69 | 0.150 |
Why?
|
| Drug Design | 1 | 2017 | 124 | 0.140 |
Why?
|
| Placebo Effect | 2 | 2014 | 31 | 0.140 |
Why?
|
| United Kingdom | 3 | 2020 | 164 | 0.140 |
Why?
|
| Drug Synergism | 2 | 2007 | 303 | 0.140 |
Why?
|
| Fertility | 1 | 2017 | 115 | 0.140 |
Why?
|
| Leukoencephalopathy, Progressive Multifocal | 2 | 2014 | 13 | 0.140 |
Why?
|
| Algorithms | 4 | 2014 | 1830 | 0.140 |
Why?
|
| Prostate-Specific Antigen | 1 | 2018 | 353 | 0.140 |
Why?
|
| Smoking Cessation | 3 | 2012 | 230 | 0.140 |
Why?
|
| Cross-Over Studies | 3 | 2009 | 399 | 0.140 |
Why?
|
| Nod2 Signaling Adaptor Protein | 4 | 2010 | 13 | 0.140 |
Why?
|
| Receptors, Lysosphingolipid | 1 | 2016 | 36 | 0.140 |
Why?
|
| Guidelines as Topic | 2 | 2007 | 162 | 0.140 |
Why?
|
| Receptors, Calcitriol | 2 | 2016 | 129 | 0.140 |
Why?
|
| Clinical Decision-Making | 1 | 2018 | 257 | 0.140 |
Why?
|
| Digestive System Fistula | 3 | 2010 | 3 | 0.140 |
Why?
|
| Reactive Oxygen Species | 1 | 2019 | 480 | 0.140 |
Why?
|
| Transition to Adult Care | 1 | 2016 | 22 | 0.140 |
Why?
|
| Drug Combinations | 2 | 2007 | 224 | 0.140 |
Why?
|
| Chi-Square Distribution | 3 | 2007 | 364 | 0.140 |
Why?
|
| Interleukin-12 Subunit p40 | 1 | 2015 | 12 | 0.130 |
Why?
|
| Cell Adhesion Molecules | 2 | 2006 | 163 | 0.130 |
Why?
|
| Clinical Medicine | 1 | 2015 | 34 | 0.130 |
Why?
|
| Chromosomes, Human, Pair 16 | 3 | 2000 | 79 | 0.130 |
Why?
|
| Integrin alpha4 | 3 | 2013 | 11 | 0.130 |
Why?
|
| Lymphocytes | 2 | 2015 | 464 | 0.130 |
Why?
|
| Digestive System Surgical Procedures | 3 | 2005 | 120 | 0.130 |
Why?
|
| Monitoring, Physiologic | 3 | 2012 | 268 | 0.130 |
Why?
|
| T-Lymphocytes | 4 | 2023 | 1195 | 0.130 |
Why?
|
| Autoantibodies | 1 | 1996 | 267 | 0.130 |
Why?
|
| Cell Migration Inhibition | 1 | 2014 | 8 | 0.130 |
Why?
|
| Endoscopy | 3 | 2013 | 332 | 0.120 |
Why?
|
| Fistula | 1 | 2014 | 42 | 0.120 |
Why?
|
| Radiation Protection | 1 | 2014 | 25 | 0.120 |
Why?
|
| Drug Substitution | 1 | 2014 | 25 | 0.120 |
Why?
|
| Acute Kidney Injury | 1 | 2018 | 296 | 0.120 |
Why?
|
| Aminosalicylic Acid | 1 | 2013 | 1 | 0.120 |
Why?
|
| Oxides | 1 | 2014 | 43 | 0.120 |
Why?
|
| Postoperative Period | 3 | 2016 | 303 | 0.120 |
Why?
|
| Calcineurin | 1 | 2013 | 16 | 0.120 |
Why?
|
| Intestinal Obstruction | 3 | 2006 | 88 | 0.120 |
Why?
|
| Radiation, Ionizing | 1 | 2014 | 121 | 0.120 |
Why?
|
| Radiography, Thoracic | 1 | 2015 | 320 | 0.120 |
Why?
|
| Carbon | 1 | 2014 | 80 | 0.120 |
Why?
|
| Probiotics | 2 | 2008 | 81 | 0.120 |
Why?
|
| Cholangitis | 1 | 1993 | 19 | 0.120 |
Why?
|
| Pulmonary Embolism | 1 | 1996 | 222 | 0.120 |
Why?
|
| Mucous Membrane | 1 | 2013 | 83 | 0.120 |
Why?
|
| Vaginal Fistula | 1 | 1993 | 5 | 0.120 |
Why?
|
| Occupational Exposure | 1 | 2014 | 80 | 0.110 |
Why?
|
| Ciprofloxacin | 1 | 2013 | 29 | 0.110 |
Why?
|
| Observer Variation | 4 | 2018 | 603 | 0.110 |
Why?
|
| Methyltransferases | 3 | 2011 | 182 | 0.110 |
Why?
|
| Consensus | 2 | 2022 | 336 | 0.110 |
Why?
|
| Enteritis | 1 | 2013 | 21 | 0.110 |
Why?
|
| Precision Medicine | 1 | 2017 | 395 | 0.110 |
Why?
|
| Pneumonia, Pneumocystis | 1 | 1992 | 18 | 0.110 |
Why?
|
| Defecation | 2 | 2009 | 23 | 0.110 |
Why?
|
| Gastritis | 1 | 2013 | 32 | 0.110 |
Why?
|
| Reproducibility of Results | 5 | 2018 | 2706 | 0.110 |
Why?
|
| Sickness Impact Profile | 2 | 2011 | 27 | 0.110 |
Why?
|
| Sigmoid Diseases | 1 | 1992 | 4 | 0.110 |
Why?
|
| Body Weight | 1 | 2013 | 459 | 0.110 |
Why?
|
| Intestinal Pseudo-Obstruction | 1 | 1992 | 5 | 0.110 |
Why?
|
| Abatacept | 1 | 2012 | 83 | 0.110 |
Why?
|
| Guanine Nucleotides | 1 | 2011 | 14 | 0.100 |
Why?
|
| Bacterial Infections | 2 | 2006 | 182 | 0.100 |
Why?
|
| Thionucleotides | 1 | 2011 | 56 | 0.100 |
Why?
|
| Phenotype | 5 | 2021 | 2380 | 0.100 |
Why?
|
| Quality Indicators, Health Care | 1 | 2013 | 145 | 0.100 |
Why?
|
| Cytomegalovirus | 1 | 2011 | 76 | 0.100 |
Why?
|
| Immunoconjugates | 1 | 2012 | 106 | 0.100 |
Why?
|
| Proto-Oncogenes | 1 | 2011 | 61 | 0.100 |
Why?
|
| Attitude | 1 | 2012 | 127 | 0.100 |
Why?
|
| Tomography, X-Ray Computed | 2 | 2015 | 2601 | 0.100 |
Why?
|
| Age Factors | 4 | 2007 | 1852 | 0.100 |
Why?
|
| Odds Ratio | 5 | 2003 | 680 | 0.100 |
Why?
|
| Chromosomes, Human, Pair 3 | 2 | 2002 | 54 | 0.100 |
Why?
|
| Cytomegalovirus Infections | 1 | 2011 | 144 | 0.100 |
Why?
|
| Capsules | 6 | 2002 | 38 | 0.100 |
Why?
|
| Patient Acuity | 2 | 2020 | 33 | 0.100 |
Why?
|
| Carcinoma | 2 | 1995 | 436 | 0.090 |
Why?
|
| Enzyme Inhibitors | 1 | 2013 | 639 | 0.090 |
Why?
|
| Receptors, Tumor Necrosis Factor | 2 | 2001 | 88 | 0.090 |
Why?
|
| Reference Values | 2 | 2018 | 674 | 0.090 |
Why?
|
| Writing | 1 | 2010 | 29 | 0.090 |
Why?
|
| Mexico | 1 | 2010 | 67 | 0.090 |
Why?
|
| Analysis of Variance | 4 | 2002 | 912 | 0.090 |
Why?
|
| Liver | 3 | 2011 | 1230 | 0.090 |
Why?
|
| Interleukin-10 | 2 | 2000 | 149 | 0.090 |
Why?
|
| Editorial Policies | 1 | 2010 | 32 | 0.090 |
Why?
|
| Leukemia, Myeloid | 3 | 1995 | 249 | 0.090 |
Why?
|
| Folic Acid Deficiency | 1 | 1989 | 7 | 0.090 |
Why?
|
| Cross-Cultural Comparison | 1 | 2009 | 34 | 0.090 |
Why?
|
| Photopheresis | 1 | 2009 | 12 | 0.090 |
Why?
|
| Reoperation | 1 | 2012 | 597 | 0.090 |
Why?
|
| Folic Acid | 1 | 1989 | 60 | 0.090 |
Why?
|
| Rad51 Recombinase | 2 | 2021 | 80 | 0.090 |
Why?
|
| Chromosomes, Human, Pair 1 | 2 | 2000 | 100 | 0.090 |
Why?
|
| Clinical Protocols | 2 | 2004 | 156 | 0.090 |
Why?
|
| Canada | 1 | 2009 | 204 | 0.090 |
Why?
|
| Ghrelin | 1 | 2009 | 29 | 0.080 |
Why?
|
| Parenteral Nutrition | 2 | 1986 | 60 | 0.080 |
Why?
|
| Maximum Tolerated Dose | 3 | 2015 | 270 | 0.080 |
Why?
|
| Autoimmunity | 1 | 2010 | 160 | 0.080 |
Why?
|
| Spiro Compounds | 1 | 2009 | 25 | 0.080 |
Why?
|
| Insurance, Health, Reimbursement | 1 | 2009 | 59 | 0.080 |
Why?
|
| Feasibility Studies | 3 | 2007 | 751 | 0.080 |
Why?
|
| Cytochrome P-450 CYP3A | 1 | 2008 | 43 | 0.080 |
Why?
|
| Drug Interactions | 1 | 2009 | 248 | 0.080 |
Why?
|
| Carrier Proteins | 2 | 2003 | 673 | 0.080 |
Why?
|
| Muscular Atrophy | 1 | 2009 | 41 | 0.080 |
Why?
|
| Body Composition | 1 | 2009 | 68 | 0.080 |
Why?
|
| Chromosome Mapping | 4 | 2006 | 1074 | 0.080 |
Why?
|
| Transcriptome | 1 | 2013 | 580 | 0.080 |
Why?
|
| Decision Support Techniques | 1 | 2010 | 160 | 0.080 |
Why?
|
| Immunoglobulin G | 2 | 2001 | 456 | 0.080 |
Why?
|
| Cell Proliferation | 1 | 2014 | 1579 | 0.080 |
Why?
|
| Wine | 1 | 2008 | 5 | 0.080 |
Why?
|
| Interferon-beta | 1 | 2009 | 125 | 0.080 |
Why?
|
| Preventive Medicine | 1 | 2008 | 17 | 0.080 |
Why?
|
| Video Recording | 3 | 2015 | 190 | 0.080 |
Why?
|
| Data Interpretation, Statistical | 2 | 2016 | 297 | 0.080 |
Why?
|
| Psychology, Social | 1 | 2008 | 9 | 0.080 |
Why?
|
| Insulin-Like Growth Factor I | 1 | 2009 | 114 | 0.080 |
Why?
|
| Lupus Erythematosus, Systemic | 1 | 2010 | 206 | 0.080 |
Why?
|
| Curcumin | 1 | 2008 | 15 | 0.080 |
Why?
|
| Haplotypes | 2 | 2008 | 642 | 0.080 |
Why?
|
| Taste | 1 | 2008 | 28 | 0.080 |
Why?
|
| Tablets | 1 | 2009 | 118 | 0.080 |
Why?
|
| Glycoproteins | 1 | 1989 | 234 | 0.080 |
Why?
|
| Rifamycins | 1 | 2007 | 6 | 0.080 |
Why?
|
| Cisapride | 1 | 2007 | 4 | 0.080 |
Why?
|
| Domperidone | 1 | 2007 | 8 | 0.080 |
Why?
|
| Growth | 1 | 2007 | 43 | 0.080 |
Why?
|
| Vaccination | 1 | 2009 | 254 | 0.080 |
Why?
|
| HCT116 Cells | 2 | 2021 | 151 | 0.080 |
Why?
|
| Antifoaming Agents | 1 | 2007 | 1 | 0.080 |
Why?
|
| Leukocyte Count | 3 | 2003 | 220 | 0.080 |
Why?
|
| Digestive System Physiological Phenomena | 1 | 2007 | 4 | 0.080 |
Why?
|
| Nutritional Requirements | 1 | 2007 | 17 | 0.080 |
Why?
|
| Thiazolidinediones | 1 | 2007 | 82 | 0.080 |
Why?
|
| Taxes | 1 | 2007 | 3 | 0.080 |
Why?
|
| Food Service, Hospital | 1 | 2007 | 4 | 0.080 |
Why?
|
| Salicylates | 2 | 1999 | 25 | 0.080 |
Why?
|
| Mass Screening | 2 | 2008 | 619 | 0.070 |
Why?
|
| Tumor Necrosis Factors | 1 | 2007 | 14 | 0.070 |
Why?
|
| Antigens, Neoplasm | 1 | 1989 | 325 | 0.070 |
Why?
|
| Cyclic Nucleotide Phosphodiesterases, Type 4 | 1 | 2006 | 9 | 0.070 |
Why?
|
| 3',5'-Cyclic-AMP Phosphodiesterases | 1 | 2006 | 8 | 0.070 |
Why?
|
| Cyclophosphamide | 3 | 1996 | 299 | 0.070 |
Why?
|
| Gases | 1 | 2007 | 30 | 0.070 |
Why?
|
| Gastrointestinal Transit | 1 | 2007 | 19 | 0.070 |
Why?
|
| Organizations | 1 | 2007 | 17 | 0.070 |
Why?
|
| Narration | 1 | 2007 | 16 | 0.070 |
Why?
|
| Computers, Handheld | 1 | 2007 | 32 | 0.070 |
Why?
|
| Intercellular Signaling Peptides and Proteins | 1 | 2008 | 179 | 0.070 |
Why?
|
| Cytotoxins | 1 | 1986 | 15 | 0.070 |
Why?
|
| Pregnancy Rate | 1 | 2006 | 20 | 0.070 |
Why?
|
| Longitudinal Studies | 3 | 2000 | 1019 | 0.070 |
Why?
|
| Neoplasm Grading | 2 | 2018 | 357 | 0.070 |
Why?
|
| Intestinal Perforation | 1 | 2007 | 34 | 0.070 |
Why?
|
| Health Facilities | 1 | 2007 | 38 | 0.070 |
Why?
|
| Metronidazole | 2 | 2000 | 26 | 0.070 |
Why?
|
| Preoperative Care | 1 | 1989 | 397 | 0.070 |
Why?
|
| Constipation | 1 | 2007 | 63 | 0.070 |
Why?
|
| Cyclooxygenase 2 Inhibitors | 1 | 2006 | 33 | 0.070 |
Why?
|
| Adsorption | 1 | 2006 | 54 | 0.070 |
Why?
|
| Intestinal Absorption | 1 | 2007 | 124 | 0.070 |
Why?
|
| Medical Records | 1 | 2007 | 119 | 0.070 |
Why?
|
| Energy Intake | 1 | 2006 | 98 | 0.070 |
Why?
|
| Survival Analysis | 3 | 2004 | 1538 | 0.070 |
Why?
|
| Endoscopy, Digestive System | 3 | 2001 | 65 | 0.070 |
Why?
|
| Fat Emulsions, Intravenous | 1 | 1986 | 13 | 0.070 |
Why?
|
| North America | 3 | 2014 | 180 | 0.070 |
Why?
|
| Health Status Indicators | 1 | 2006 | 105 | 0.070 |
Why?
|
| Sample Size | 1 | 2006 | 130 | 0.070 |
Why?
|
| Helicobacter Infections | 1 | 2006 | 34 | 0.070 |
Why?
|
| Vibrio parahaemolyticus | 1 | 2005 | 2 | 0.070 |
Why?
|
| Helicobacter pylori | 1 | 2006 | 35 | 0.070 |
Why?
|
| Alaska | 1 | 2005 | 17 | 0.070 |
Why?
|
| Ostreidae | 1 | 2005 | 3 | 0.070 |
Why?
|
| Health Education | 1 | 2006 | 101 | 0.070 |
Why?
|
| Jews | 2 | 2003 | 42 | 0.070 |
Why?
|
| Bacterial Toxins | 1 | 1986 | 111 | 0.070 |
Why?
|
| Integrin alpha Chains | 1 | 2005 | 15 | 0.070 |
Why?
|
| Emotions | 1 | 2009 | 341 | 0.070 |
Why?
|
| Regression Analysis | 4 | 2010 | 596 | 0.070 |
Why?
|
| Mice | 4 | 2024 | 11356 | 0.070 |
Why?
|
| Sirolimus | 1 | 2007 | 170 | 0.070 |
Why?
|
| Patient Care | 1 | 2007 | 100 | 0.070 |
Why?
|
| Chemistry, Pharmaceutical | 1 | 2006 | 59 | 0.070 |
Why?
|
| Illinois | 1 | 2007 | 462 | 0.070 |
Why?
|
| Recombinant Proteins | 4 | 2000 | 1015 | 0.070 |
Why?
|
| Viscera | 1 | 2005 | 17 | 0.070 |
Why?
|
| Pancreatitis | 1 | 1986 | 87 | 0.070 |
Why?
|
| Nuclear Proteins | 1 | 2010 | 696 | 0.070 |
Why?
|
| Laos | 1 | 2005 | 4 | 0.070 |
Why?
|
| Histocytochemistry | 2 | 2017 | 130 | 0.070 |
Why?
|
| Mesenteric Veins | 1 | 2005 | 34 | 0.070 |
Why?
|
| Paclitaxel | 1 | 2007 | 460 | 0.070 |
Why?
|
| Antineoplastic Agents, Alkylating | 2 | 1996 | 138 | 0.070 |
Why?
|
| Equipment Design | 1 | 2006 | 407 | 0.060 |
Why?
|
| Polymorphism, Single Nucleotide | 3 | 2010 | 2357 | 0.060 |
Why?
|
| Recombinant Fusion Proteins | 2 | 1997 | 557 | 0.060 |
Why?
|
| Pregnancy Trimester, Third | 1 | 2004 | 70 | 0.060 |
Why?
|
| Cells, Cultured | 3 | 2015 | 2819 | 0.060 |
Why?
|
| Kaplan-Meier Estimate | 3 | 2013 | 861 | 0.060 |
Why?
|
| Fatty Liver | 1 | 2006 | 125 | 0.060 |
Why?
|
| HLA-DRB1 Chains | 1 | 2004 | 28 | 0.060 |
Why?
|
| Combined Modality Therapy | 4 | 1999 | 1686 | 0.060 |
Why?
|
| Matrix Metalloproteinase 14 | 1 | 2024 | 5 | 0.060 |
Why?
|
| Research Subjects | 1 | 2005 | 73 | 0.060 |
Why?
|
| Absenteeism | 1 | 2004 | 9 | 0.060 |
Why?
|
| Primary Health Care | 1 | 2007 | 339 | 0.060 |
Why?
|
| Diagnostic Errors | 1 | 2005 | 160 | 0.060 |
Why?
|
| Linkage Disequilibrium | 2 | 2008 | 473 | 0.060 |
Why?
|
| Fever | 1 | 2004 | 125 | 0.060 |
Why?
|
| Confidence Intervals | 3 | 1994 | 229 | 0.060 |
Why?
|
| Bone Density | 1 | 2005 | 209 | 0.060 |
Why?
|
| Drainage | 1 | 2004 | 157 | 0.060 |
Why?
|
| Clinical Trials, Phase II as Topic | 1 | 2004 | 176 | 0.060 |
Why?
|
| Structure-Activity Relationship | 1 | 2004 | 408 | 0.060 |
Why?
|
| Fibroblast Growth Factor 10 | 1 | 2003 | 6 | 0.060 |
Why?
|
| Exercise | 1 | 2007 | 315 | 0.060 |
Why?
|
| Proportional Hazards Models | 3 | 2018 | 860 | 0.060 |
Why?
|
| Infant | 1 | 2010 | 3047 | 0.060 |
Why?
|
| Administration, Intravenous | 1 | 2023 | 50 | 0.060 |
Why?
|
| Risk | 3 | 2011 | 674 | 0.060 |
Why?
|
| Probability | 1 | 2004 | 355 | 0.060 |
Why?
|
| Cell Cycle Proteins | 1 | 2006 | 388 | 0.060 |
Why?
|
| Etanercept | 2 | 2001 | 32 | 0.060 |
Why?
|
| Saccharomyces cerevisiae Proteins | 1 | 2006 | 276 | 0.060 |
Why?
|
| Body Mass Index | 1 | 2006 | 770 | 0.060 |
Why?
|
| Lymphocyte Activation | 1 | 2006 | 728 | 0.060 |
Why?
|
| Therapeutic Equivalency | 1 | 2022 | 12 | 0.060 |
Why?
|
| Informed Consent | 1 | 2005 | 266 | 0.050 |
Why?
|
| Leukemia, Monocytic, Acute | 1 | 1982 | 14 | 0.050 |
Why?
|
| Antibodies, Antinuclear | 3 | 2007 | 83 | 0.050 |
Why?
|
| Age of Onset | 4 | 2007 | 310 | 0.050 |
Why?
|
| Venous Thrombosis | 1 | 2005 | 243 | 0.050 |
Why?
|
| Syndrome | 1 | 2003 | 446 | 0.050 |
Why?
|
| Methylprednisolone | 1 | 2022 | 66 | 0.050 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 1 | 2003 | 376 | 0.050 |
Why?
|
| Survival Rate | 3 | 2011 | 1864 | 0.050 |
Why?
|
| Patient Compliance | 4 | 2007 | 228 | 0.050 |
Why?
|
| Purpura, Thrombotic Thrombocytopenic | 1 | 2002 | 16 | 0.050 |
Why?
|
| Multivariate Analysis | 2 | 2020 | 1001 | 0.050 |
Why?
|
| Sex Factors | 1 | 2005 | 1055 | 0.050 |
Why?
|
| Neovascularization, Pathologic | 1 | 2024 | 353 | 0.050 |
Why?
|
| Plasma Exchange | 1 | 2002 | 29 | 0.050 |
Why?
|
| Bradycardia | 1 | 2021 | 39 | 0.050 |
Why?
|
| Lod Score | 4 | 2006 | 152 | 0.050 |
Why?
|
| Intention to Treat Analysis | 1 | 2021 | 72 | 0.050 |
Why?
|
| Ku Autoantigen | 1 | 2021 | 12 | 0.050 |
Why?
|
| Frameshift Mutation | 1 | 2001 | 51 | 0.050 |
Why?
|
| Real-Time Polymerase Chain Reaction | 2 | 2013 | 273 | 0.050 |
Why?
|
| Cyclosporins | 1 | 2001 | 59 | 0.050 |
Why?
|
| Aftercare | 1 | 2022 | 85 | 0.050 |
Why?
|
| Folic Acid Antagonists | 1 | 2000 | 19 | 0.050 |
Why?
|
| Mice, Inbred C57BL | 2 | 2021 | 3095 | 0.050 |
Why?
|
| Peristalsis | 1 | 2000 | 10 | 0.050 |
Why?
|
| Statistics, Nonparametric | 2 | 1999 | 308 | 0.050 |
Why?
|
| Leukemia, Hairy Cell | 1 | 1981 | 186 | 0.050 |
Why?
|
| Coculture Techniques | 1 | 2021 | 164 | 0.050 |
Why?
|
| Suppositories | 1 | 2000 | 3 | 0.050 |
Why?
|
| Poly(ADP-ribose) Polymerase Inhibitors | 1 | 2021 | 72 | 0.050 |
Why?
|
| Adaptation, Psychological | 1 | 2021 | 157 | 0.050 |
Why?
|
| Down-Regulation | 2 | 2013 | 506 | 0.050 |
Why?
|
| Bacterial Proteins | 1 | 1986 | 864 | 0.050 |
Why?
|
| Decision Making | 1 | 2006 | 642 | 0.050 |
Why?
|
| Chemical and Drug Induced Liver Injury | 1 | 2000 | 69 | 0.050 |
Why?
|
| Genetic Markers | 3 | 2013 | 476 | 0.050 |
Why?
|
| Salvage Therapy | 2 | 2013 | 233 | 0.050 |
Why?
|
| Data Collection | 2 | 1999 | 372 | 0.040 |
Why?
|
| Databases, Genetic | 1 | 2021 | 260 | 0.040 |
Why?
|
| Suture Techniques | 1 | 2000 | 135 | 0.040 |
Why?
|
| Interleukin-11 | 1 | 1999 | 20 | 0.040 |
Why?
|
| Gene Expression Profiling | 2 | 2017 | 1384 | 0.040 |
Why?
|
| Cutaneous Fistula | 1 | 1999 | 11 | 0.040 |
Why?
|
| Xenograft Model Antitumor Assays | 1 | 2021 | 458 | 0.040 |
Why?
|
| Electromyography | 1 | 1999 | 183 | 0.040 |
Why?
|
| Hospitals | 1 | 2022 | 294 | 0.040 |
Why?
|
| Predictive Value of Tests | 2 | 2018 | 1673 | 0.040 |
Why?
|
| Gene Expression Regulation, Neoplastic | 2 | 2017 | 1197 | 0.040 |
Why?
|
| Patient Discharge | 1 | 2022 | 300 | 0.040 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 2 | 1996 | 878 | 0.040 |
Why?
|
| Chromosomes, Human, Pair 12 | 1 | 1998 | 65 | 0.040 |
Why?
|
| Health Services | 1 | 1999 | 55 | 0.040 |
Why?
|
| Proctocolitis | 1 | 1998 | 3 | 0.040 |
Why?
|
| Chromosomes, Human, Pair 4 | 1 | 1998 | 48 | 0.040 |
Why?
|
| Genetic Variation | 2 | 2006 | 1351 | 0.040 |
Why?
|
| Epistasis, Genetic | 1 | 1998 | 86 | 0.040 |
Why?
|
| Breast Neoplasms | 3 | 1996 | 2903 | 0.040 |
Why?
|
| Lipopolysaccharides | 2 | 2014 | 286 | 0.040 |
Why?
|
| Fatal Outcome | 1 | 1998 | 295 | 0.040 |
Why?
|
| Reference Standards | 1 | 2018 | 159 | 0.040 |
Why?
|
| Cost of Illness | 1 | 1998 | 150 | 0.040 |
Why?
|
| Monitoring, Ambulatory | 1 | 1997 | 32 | 0.040 |
Why?
|
| Transfection | 2 | 2010 | 896 | 0.040 |
Why?
|
| Opportunistic Infections | 1 | 2017 | 59 | 0.040 |
Why?
|
| Constriction, Pathologic | 2 | 2006 | 213 | 0.040 |
Why?
|
| Lipoxygenase Inhibitors | 1 | 1997 | 33 | 0.040 |
Why?
|
| Fatty Acids, Volatile | 1 | 1997 | 32 | 0.040 |
Why?
|
| Homeodomain Proteins | 1 | 2021 | 536 | 0.040 |
Why?
|
| Delphi Technique | 1 | 2016 | 80 | 0.040 |
Why?
|
| Comorbidity | 1 | 2000 | 944 | 0.040 |
Why?
|
| Interleukin-3 | 1 | 1996 | 36 | 0.040 |
Why?
|
| International Agencies | 1 | 2016 | 34 | 0.040 |
Why?
|
| Diphenhydramine | 1 | 1996 | 17 | 0.040 |
Why?
|
| Quinolines | 1 | 1997 | 95 | 0.040 |
Why?
|
| Occludin | 1 | 2016 | 66 | 0.040 |
Why?
|
| Interleukin-8 | 1 | 2016 | 86 | 0.040 |
Why?
|
| Antibodies, Antineutrophil Cytoplasmic | 1 | 1996 | 21 | 0.040 |
Why?
|
| Mice, Knockout | 1 | 2021 | 1924 | 0.030 |
Why?
|
| Zonula Occludens-1 Protein | 1 | 2016 | 70 | 0.030 |
Why?
|
| Histamine H1 Antagonists | 1 | 1996 | 40 | 0.030 |
Why?
|
| Granulocyte-Macrophage Colony-Stimulating Factor | 1 | 1996 | 112 | 0.030 |
Why?
|
| Prostaglandin Antagonists | 1 | 1995 | 7 | 0.030 |
Why?
|
| Databases, Factual | 1 | 1999 | 816 | 0.030 |
Why?
|
| Proteins | 1 | 2001 | 777 | 0.030 |
Why?
|
| Enteral Nutrition | 1 | 1996 | 102 | 0.030 |
Why?
|
| Immunity, Cellular | 1 | 1996 | 177 | 0.030 |
Why?
|
| Cadherins | 1 | 2016 | 151 | 0.030 |
Why?
|
| Activities of Daily Living | 1 | 2016 | 204 | 0.030 |
Why?
|
| Pregnancy Outcome | 1 | 2017 | 247 | 0.030 |
Why?
|
| NF-kappa B | 2 | 2013 | 445 | 0.030 |
Why?
|
| Single-Blind Method | 1 | 2015 | 153 | 0.030 |
Why?
|
| Signal Transduction | 2 | 2017 | 3243 | 0.030 |
Why?
|
| Phytohemagglutinins | 1 | 2014 | 22 | 0.030 |
Why?
|
| Israel | 1 | 2014 | 55 | 0.030 |
Why?
|
| Minnesota | 1 | 1994 | 46 | 0.030 |
Why?
|
| Antigens, CD | 1 | 2016 | 458 | 0.030 |
Why?
|
| Interleukin-1beta | 1 | 2014 | 78 | 0.030 |
Why?
|
| Administration, Cutaneous | 1 | 1994 | 58 | 0.030 |
Why?
|
| CD28 Antigens | 1 | 2014 | 88 | 0.030 |
Why?
|
| Hematopoietic Stem Cells | 1 | 1996 | 292 | 0.030 |
Why?
|
| Microspheres | 1 | 2014 | 101 | 0.030 |
Why?
|
| Polymerase Chain Reaction | 2 | 2010 | 928 | 0.030 |
Why?
|
| Trinitrobenzenesulfonic Acid | 1 | 2013 | 16 | 0.030 |
Why?
|
| Dextran Sulfate | 1 | 2013 | 68 | 0.030 |
Why?
|
| Gene Frequency | 2 | 2008 | 677 | 0.030 |
Why?
|
| Radiation Dosage | 1 | 2014 | 227 | 0.030 |
Why?
|
| Discriminant Analysis | 1 | 2013 | 66 | 0.030 |
Why?
|
| Area Under Curve | 1 | 2014 | 334 | 0.030 |
Why?
|
| Group Processes | 1 | 2013 | 31 | 0.030 |
Why?
|
| Adaptive Immunity | 1 | 2014 | 164 | 0.030 |
Why?
|
| Tobacco Smoke Pollution | 1 | 1993 | 23 | 0.030 |
Why?
|
| Hypertension | 1 | 2021 | 1142 | 0.030 |
Why?
|
| Tertiary Care Centers | 1 | 2013 | 94 | 0.030 |
Why?
|
| Hydrocortisone | 1 | 1994 | 298 | 0.030 |
Why?
|
| Apoptosis Regulatory Proteins | 1 | 2013 | 199 | 0.030 |
Why?
|
| Aneuploidy | 1 | 1992 | 55 | 0.030 |
Why?
|
| Transcriptional Activation | 1 | 2013 | 280 | 0.030 |
Why?
|
| DNA, Complementary | 1 | 2013 | 393 | 0.030 |
Why?
|
| Tight Junctions | 1 | 2013 | 149 | 0.030 |
Why?
|
| Polymorphism, Restriction Fragment Length | 1 | 2012 | 147 | 0.030 |
Why?
|
| Suspensions | 1 | 2011 | 6 | 0.030 |
Why?
|
| Myelodysplastic Syndromes | 1 | 1995 | 346 | 0.030 |
Why?
|
| Anastomosis, Surgical | 1 | 2013 | 267 | 0.030 |
Why?
|
| Tumor Suppressor Proteins | 1 | 2013 | 279 | 0.030 |
Why?
|
| Medication Adherence | 1 | 2013 | 129 | 0.020 |
Why?
|
| Regional Blood Flow | 1 | 2011 | 197 | 0.020 |
Why?
|
| Metagenome | 1 | 2012 | 102 | 0.020 |
Why?
|
| Interdisciplinary Communication | 1 | 2012 | 130 | 0.020 |
Why?
|
| RNA, Ribosomal, 16S | 1 | 2012 | 241 | 0.020 |
Why?
|
| Tobacco Use Disorder | 1 | 2012 | 108 | 0.020 |
Why?
|
| Polymethacrylic Acids | 1 | 1990 | 3 | 0.020 |
Why?
|
| Chewing Gum | 1 | 1990 | 4 | 0.020 |
Why?
|
| In Situ Hybridization | 1 | 2011 | 307 | 0.020 |
Why?
|
| Sentinel Surveillance | 1 | 2010 | 23 | 0.020 |
Why?
|
| Polyvinyls | 1 | 1990 | 17 | 0.020 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 1 | 2013 | 689 | 0.020 |
Why?
|
| Tumor Necrosis Factor alpha-Induced Protein 3 | 1 | 2010 | 15 | 0.020 |
Why?
|
| Patient Safety | 1 | 2013 | 212 | 0.020 |
Why?
|
| Up-Regulation | 1 | 2013 | 715 | 0.020 |
Why?
|
| Protein Structure, Quaternary | 1 | 2010 | 99 | 0.020 |
Why?
|
| Quality Improvement | 1 | 2014 | 429 | 0.020 |
Why?
|
| Immunoprecipitation | 1 | 2010 | 134 | 0.020 |
Why?
|
| Statistics as Topic | 1 | 2011 | 238 | 0.020 |
Why?
|
| Immunoblotting | 1 | 2010 | 268 | 0.020 |
Why?
|
| Methoxsalen | 1 | 2009 | 15 | 0.020 |
Why?
|
| Registries | 1 | 1993 | 703 | 0.020 |
Why?
|
| Mice, Transgenic | 1 | 2013 | 1540 | 0.020 |
Why?
|
| Blotting, Western | 1 | 2011 | 782 | 0.020 |
Why?
|
| Interferon beta-1a | 1 | 2009 | 18 | 0.020 |
Why?
|
| Photosensitizing Agents | 1 | 2009 | 48 | 0.020 |
Why?
|
| Epithelial Cells | 1 | 2013 | 669 | 0.020 |
Why?
|
| Cecum | 1 | 1989 | 68 | 0.020 |
Why?
|
| Motivation | 1 | 2012 | 288 | 0.020 |
Why?
|
| Evaluation Studies as Topic | 1 | 1989 | 274 | 0.020 |
Why?
|
| Immunoenzyme Techniques | 1 | 1989 | 303 | 0.020 |
Why?
|
| Electrolytes | 1 | 1988 | 52 | 0.020 |
Why?
|
| Midazolam | 1 | 2008 | 48 | 0.020 |
Why?
|
| Headache | 1 | 2009 | 73 | 0.020 |
Why?
|
| Immunohistochemistry | 1 | 2013 | 1753 | 0.020 |
Why?
|
| Rabbits | 2 | 2005 | 636 | 0.020 |
Why?
|
| Japan | 1 | 2008 | 307 | 0.020 |
Why?
|
| Cross-Sectional Studies | 1 | 2013 | 1621 | 0.020 |
Why?
|
| Anal Canal | 1 | 1988 | 89 | 0.020 |
Why?
|
| Apoptosis | 1 | 2013 | 1683 | 0.020 |
Why?
|
| Sacroiliac Joint | 1 | 2006 | 7 | 0.020 |
Why?
|
| Nod1 Signaling Adaptor Protein | 1 | 2006 | 2 | 0.020 |
Why?
|
| Emulsions | 1 | 1986 | 19 | 0.020 |
Why?
|
| Rectal Diseases | 1 | 2006 | 24 | 0.020 |
Why?
|
| Stomach Diseases | 1 | 2006 | 19 | 0.020 |
Why?
|
| Duodenal Diseases | 1 | 2006 | 24 | 0.020 |
Why?
|
| Polymorphism, Genetic | 1 | 2010 | 819 | 0.020 |
Why?
|
| Esophageal Diseases | 1 | 2006 | 26 | 0.020 |
Why?
|
| Uveitis | 1 | 2006 | 29 | 0.020 |
Why?
|
| JC Virus | 1 | 2005 | 5 | 0.020 |
Why?
|
| Influenza, Human | 1 | 2009 | 329 | 0.020 |
Why?
|
| Endpoint Determination | 1 | 2005 | 60 | 0.020 |
Why?
|
| RNA, Messenger | 1 | 2011 | 1981 | 0.020 |
Why?
|
| Short Bowel Syndrome | 1 | 2005 | 37 | 0.020 |
Why?
|
| Minority Groups | 1 | 2006 | 137 | 0.020 |
Why?
|
| Liver Function Tests | 1 | 1985 | 93 | 0.020 |
Why?
|
| Tissue Culture Techniques | 1 | 2005 | 79 | 0.020 |
Why?
|
| Drug Tolerance | 1 | 2004 | 63 | 0.020 |
Why?
|
| Intestine, Large | 1 | 1984 | 16 | 0.020 |
Why?
|
| CD4-Positive T-Lymphocytes | 1 | 2007 | 425 | 0.020 |
Why?
|
| Random Allocation | 1 | 2005 | 332 | 0.020 |
Why?
|
| Diverticulum, Colon | 1 | 1984 | 10 | 0.020 |
Why?
|
| Campylobacter Infections | 1 | 1984 | 12 | 0.020 |
Why?
|
| Drug Hypersensitivity | 1 | 1984 | 37 | 0.020 |
Why?
|
| Models, Animal | 1 | 2005 | 263 | 0.020 |
Why?
|
| Adaptor Proteins, Signal Transducing | 1 | 2006 | 302 | 0.020 |
Why?
|
| DNA-Binding Proteins | 1 | 2010 | 1208 | 0.010 |
Why?
|
| CD8-Positive T-Lymphocytes | 1 | 2007 | 558 | 0.010 |
Why?
|
| Physical Examination | 1 | 1984 | 149 | 0.010 |
Why?
|
| Software | 1 | 2007 | 654 | 0.010 |
Why?
|
| Length of Stay | 2 | 1996 | 704 | 0.010 |
Why?
|
| Cell Line, Tumor | 1 | 2008 | 2426 | 0.010 |
Why?
|
| Thyroxine | 1 | 1984 | 344 | 0.010 |
Why?
|
| Genome-Wide Association Study | 1 | 2010 | 1621 | 0.010 |
Why?
|
| Radiography | 1 | 1984 | 813 | 0.010 |
Why?
|
| Blastomycosis | 1 | 1981 | 6 | 0.010 |
Why?
|
| Anticoagulants | 1 | 2005 | 408 | 0.010 |
Why?
|
| Clostridium Infections | 1 | 1984 | 125 | 0.010 |
Why?
|
| DNA Mutational Analysis | 1 | 2003 | 526 | 0.010 |
Why?
|
| Mycobacterium Infections | 1 | 1981 | 15 | 0.010 |
Why?
|
| Cellulitis | 1 | 1981 | 19 | 0.010 |
Why?
|
| Splenectomy | 1 | 1981 | 82 | 0.010 |
Why?
|
| Hepatitis | 1 | 1981 | 35 | 0.010 |
Why?
|
| Patient Education as Topic | 1 | 2004 | 351 | 0.010 |
Why?
|
| Homozygote | 1 | 2001 | 200 | 0.010 |
Why?
|
| I-kappa B Proteins | 1 | 2000 | 53 | 0.010 |
Why?
|
| Abscess | 1 | 1981 | 91 | 0.010 |
Why?
|
| Patient Dropouts | 1 | 2000 | 28 | 0.010 |
Why?
|
| Injections | 1 | 2001 | 109 | 0.010 |
Why?
|
| Mutagenesis, Insertional | 1 | 2001 | 111 | 0.010 |
Why?
|
| Middle East | 1 | 2000 | 17 | 0.010 |
Why?
|
| Physical Chromosome Mapping | 1 | 2000 | 27 | 0.010 |
Why?
|
| Injections, Intramuscular | 1 | 2000 | 62 | 0.010 |
Why?
|
| Cytosine | 1 | 2001 | 127 | 0.010 |
Why?
|
| Heterozygote | 1 | 2001 | 365 | 0.010 |
Why?
|
| Family Health | 1 | 2000 | 162 | 0.010 |
Why?
|
| International Cooperation | 1 | 2000 | 127 | 0.010 |
Why?
|
| Lymphoma | 1 | 1981 | 262 | 0.010 |
Why?
|
| In Situ Hybridization, Fluorescence | 1 | 2000 | 348 | 0.010 |
Why?
|
| Protein Structure, Tertiary | 1 | 2001 | 736 | 0.010 |
Why?
|
| Pedigree | 1 | 2000 | 966 | 0.010 |
Why?
|
| Erythrocytes | 1 | 1999 | 255 | 0.010 |
Why?
|
| Disease Models, Animal | 1 | 2005 | 2231 | 0.010 |
Why?
|
| Alleles | 1 | 2001 | 1128 | 0.010 |
Why?
|
| Disease Susceptibility | 1 | 1998 | 193 | 0.010 |
Why?
|
| Leukotriene B4 | 1 | 1997 | 14 | 0.010 |
Why?
|
| Amino Acid Sequence | 1 | 2001 | 2062 | 0.010 |
Why?
|
| Base Sequence | 1 | 2001 | 2330 | 0.010 |
Why?
|
| Colony-Forming Units Assay | 1 | 1996 | 40 | 0.010 |
Why?
|
| Cell Line | 1 | 2001 | 2469 | 0.010 |
Why?
|
| Blood Cells | 1 | 1996 | 33 | 0.010 |
Why?
|
| Molecular Sequence Data | 1 | 2001 | 3030 | 0.010 |
Why?
|
| Bone Marrow Diseases | 1 | 1996 | 40 | 0.010 |
Why?
|
| Thiotepa | 1 | 1996 | 32 | 0.010 |
Why?
|
| Life Tables | 1 | 1996 | 48 | 0.010 |
Why?
|
| Premedication | 1 | 1996 | 54 | 0.010 |
Why?
|
| Thrombophlebitis | 1 | 1995 | 25 | 0.010 |
Why?
|
| Surgical Wound Dehiscence | 1 | 1995 | 37 | 0.010 |
Why?
|
| Melphalan | 1 | 1996 | 98 | 0.010 |
Why?
|
| Leukemia, Myeloid, Acute | 1 | 1981 | 763 | 0.010 |
Why?
|
| Doxorubicin | 1 | 1996 | 295 | 0.010 |
Why?
|
| Karyotyping | 1 | 1995 | 250 | 0.010 |
Why?
|
| Insurance Selection Bias | 1 | 1995 | 1 | 0.010 |
Why?
|
| Bone Marrow Transplantation | 1 | 1996 | 286 | 0.010 |
Why?
|
| Substance Withdrawal Syndrome | 1 | 1995 | 48 | 0.010 |
Why?
|
| Fluorouracil | 1 | 1996 | 556 | 0.010 |
Why?
|
| Surgical Wound Infection | 1 | 1995 | 184 | 0.010 |
Why?
|
| Palliative Care | 1 | 1996 | 257 | 0.010 |
Why?
|
| Chromosome Aberrations | 1 | 1995 | 387 | 0.010 |
Why?
|
| Genotype | 1 | 1998 | 1852 | 0.010 |
Why?
|
| Disease-Free Survival | 1 | 1996 | 1204 | 0.010 |
Why?
|
| Orosomucoid | 1 | 1991 | 1 | 0.010 |
Why?
|
| Antineoplastic Agents | 1 | 1981 | 2360 | 0.010 |
Why?
|
| Cyclic GMP | 1 | 1988 | 58 | 0.010 |
Why?
|
| Cyclic AMP | 1 | 1988 | 273 | 0.000 |
Why?
|
| Infant, Newborn | 1 | 1993 | 2379 | 0.000 |
Why?
|
| Alanine Transaminase | 1 | 1985 | 73 | 0.000 |
Why?
|
| Aspartate Aminotransferases | 1 | 1985 | 73 | 0.000 |
Why?
|
| Alkaline Phosphatase | 1 | 1985 | 132 | 0.000 |
Why?
|
| Bilirubin | 1 | 1985 | 125 | 0.000 |
Why?
|
| Blastomyces | 1 | 1981 | 2 | 0.000 |
Why?
|
| B-Lymphocytes | 1 | 1983 | 724 | 0.000 |
Why?
|
| Skin | 1 | 1981 | 554 | 0.000 |
Why?
|